Page results
-
What is malaria? Malaria is an important cause of fever in travellers returning from Africa, Asia and South America. It is an infection caused by the malaria parasite (Plasmodium), which is…
-
This page explains the options for sensitive handling of pregnancy tissue.
-
There are rail strikes currently planned for Wednesday 27, Saturday 31 of July.
-
Nine Covid-19 research studies are already taking place at UCLH and the Trust is processing more than 30 study proposals as research efforts around the virus and pandemic are ramped up.
-
RESPOND – Information for healthcare professionals and services working with asylum seekers
-
On Saturday 25 June 2022, UCLH partnered with North Middlesex University Hospital and Whittington Health to run a summer sickle cell event at Tottenham Hotspur Stadium for children and young people with sickle cell disorder.
-
Among the many cancer clinical trials opening each year at UCLH, this year will see a focus on trials of personalised cancer treatments based on precision immunotherapies.
-
This information is for children and young people with Type 1 diabetes, and their families, on how to manage high glucose levels when using an insulin pump.
-
Trial of T-cell therapy for lung cancer begins at UCLH
-
The NHS has become the first healthcare system in the world to provide a new blood group genotyping test which is set to transform care for patients living with sickle cell disorder and thalassaemia.
File results
-
FOI2017266 Viscosupplementation injections
-
FOI2017263 Self-administration of medicines policies and carers policies
-
FOI2017295 A&E attendances for acopia
-
FOI2017296 Contracts for the redevelopment of the Middlesex annexe and Royal London Hospital for Integrated Medicine
-
FOI2017307 Televisions for patients
-
FOI2017314 Deep brain stimulation procedures
-
FOI2017300 Sustainability and transformation
-
FOI2017315 Expenditure on reconciliation and validation of incomplete and missing RTT codes
-
FOI2017320 Patients with Multiple Sclerosis treated with MS disease modifying drugs
-
FOI/2023/0226 - Treatment with Nivolumab